Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dodecylacetate SCHEMBL6666620 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TDP1TSHRNAAACES2 | |
| Hexyl Acetate SCHEMBL9720409 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TDP1TSHRNAAACES2 | |
| Acetic Acid Pentyl Ester SCHEMBL28321966 | 0.98 | ALDH1A1 (0.61) | ALDH1A1TDP1TSHRNAAACES2 | |
| Acetic Acid Butyl Ester SCHEMBL2467140 | 0.93 | ALDH1A1 (0.69) | ALDH1A1TDP1TSHRNAAACES2 | |
| Acetic Acid Pentyl Ester SCHEMBL11668869 | 0.87 | ALDH1A1 (0.61) | ALDH1A1TSHRNAAACES2EPHX1 | |
| Hexyl Acetate SCHEMBL22394276 | 0.85 | ALDH1A1 (0.53) | ALDH1A1TSHRNAAACES2EPHX1 | |
| Tridecylacetate SCHEMBL157239 | 0.84 | ALDH1A1 (0.81) | ALDH1A1TSHRNAAACES2EPHX1 | |
| SCHEMBL131668 | 0.84 | ALDH1A1 (0.81) | ALDH1A1TSHRNAAACES2EPHX1 | |
| Nonylacetate SCHEMBL309051 | 0.84 | ALDH1A1 (0.81) | ALDH1A1TSHRNAAACES2EPHX1 | |
| Octyl Acetate SCHEMBL4344544 | 0.84 | ALDH1A1 (0.81) | ALDH1A1TSHRNAAACES2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292387-B1 | ENCAPSULATION PROCESS USING ANHYDRIDE MOIETIES | UNIV MCMASTER (CA) | 2004-09-15 | — | — | EP | disclosed |
| US-20040052856-A1 | Encapsulation process using anhydride moieties | MCMASTER UNIVERSITY (CA) | 2004-03-18 | — | — | US | disclosed |
| EP-1292387-A1 | ENCAPSULATION PROCESS USING ANHYDRIDE MOIETIES | McMASTER UNIVERSITY (CA) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001096012-A1 | ENCAPSULATION PROCESS USING ANHYDRIDE MOIETIES | MCMASTER UNIVERSITY (CA) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040052856-A1 | Encapsulation process using anhydride moieties | APEH, MCHR2, MCHR1 | ALDH1A1 2044/4885TDP1 4657/4885TSHR 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.